Abstract:Advances in manufacturing technology coupled with the increased potency of new biotherapeutic modalities have created an external environment where continuous manufacturing (CM) can address a growing need. Amgen has successfully implemented a hybrid CM process for a commercial lifecycle program. In this process, the bioreactor, harvest, capture column, and viral inactivation/depth filtration unit operations were integrated together in an automated, continuous module, while the remaining downstream unit operations took place in stand‐alone batch mode. CM operations are particularly suited for so‐called "high mix, low volume" manufacturing plants, where a variety of molecules are manufactured in relatively low volumes. The selected molecule fit this mold and was manufactured in a low‐capital micro‐footprint suite attached to an existing therapeutic production facility. Use of a hybrid process within an already operating facility required less capital and minimized complexity. To enable this hybrid CM process, an established fed‐batch process was converted to a perfusion process with continuous harvest. Development efforts included both process changes and the generation of a novel cell line adapted to long‐term perfusion. Chromatography resins were updated, and purification processes adapted to handle variable inputs due to the fluctuations in harvest titer from the lengthy production process. A novel automated single‐use (SU) viral inactivation (VI) skid was introduced, which entailed the development of a robust pH verification and alarm system, along with procedures for product isolation to allow discard of specific cycles. The CM process demonstrated consistent performance, meaning it met predefined performance criteria (including product quality attributes, or PQAs) when operated within established process parameters and manufactured according to applicable procedures. Using a 75% reduction in scale, it resulted in a five‐fold reduction in process media and buffer usage, a fifteen‐fold increase in mass per thaw, and an overall process productivity increase of 45‐fold (as measured by grams drug substance per liter per day.) The hybrid CM process also enabled increased material demand to be met with no change in cost of goods manufactured or plant capacity, due to the repurposing of existing facility space and the flexible duration of the hybrid CM harvest. Overall, the success of the hybrid CM platform represents an exciting opportunity to reduce costs and increase process efficiency in industry.

Process Design of a Fully Integrated Continuous Biopharmaceutical Process using Economic and Ecological Impact Assessment

Converting a Mab Downstream Process from Batch to Continuous Using Process Modeling and Process Analytical Technology.

Model-based Process Development of Continuous Chromatography for Antibody Capture: A Case Study with Twin-Column System

Model-assisted process development, characterization and design of continuous chromatography for antibody separation

Process design and application of twin-column continuous chromatography for antibody affinity separation

Analysis and Optimal Design of Batch and Two‐column Continuous Chromatographic Frontal Processes for Monoclonal Antibody Purification

Antibody Capture with Twin-Column Continuous Chromatography: Effects of Residence Time, Protein Concentration and Resin

Analysis and Optimal Design of Batch and Two-Column Continuous Chromatographic Frontal Processes for Monoclonal Antibody Purification

Developing the biofacility of the future based on continuous processing and single-use technology

End-to-end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies

Design and operation of a continuous integrated monoclonal antibody production process

Evaluating end‐to‐end continuous antibody manufacture with column‐free capture alternatives from economic, environmental, and robustness perspectives

Process performance and product quality in an integrated continuous antibody production process

A novel hybrid bioprocess strategy addressing key challenges of advanced biomanufacturing

Transfer of continuous manufacturing process principles for mAb production in a GMP environment: A step in the transition from batch to continuous

Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study

Integrated continuous production of recombinant therapeutic proteins

Continuous multi‐column capture of monoclonal antibodies with convective diffusive membrane adsorbers

Process Optimization and Economic Evaluation of Continuous Multi-Column Capture for Monoclonal Antibody – A Case Study

Techno-economic analysis of a transient plant-based platform for monoclonal antibody production

GMP implementation of a hybrid continuous manufacturing process for a recombinant non‐mAb protein—A case study